Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Antibody-mediated Rejection in Renal Transplantation
NCT01895127Phase 2Terminated
- Sponsor
- Brigham and Women's Hospital
- Start
- Nov 2013
- Primary completion
- Apr 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of eculizumab in antibody mediated rejection (AMR), sponsored by Brigham and Women's Hospital. Started Nov 2013; status: terminated.
02
Drugs
eculizumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT01895127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01895127.